8 New and Emerging Rosacea Treatments to Know in 2026

Rosacea treatment is expanding, but “newest” can mean several different things in 2026. Emrosi is one of the newest major U.S. prescription additions. Epsolay brought a newer delivery system to an older ingredient. Laser and light treatment is becoming more individualized, while PDE4 inhibitors, biologics, and neurovascular therapies are still being studied.

These options also target different problems. A treatment developed for papules and pustules may do little for visible vessels or persistent redness. So the useful question is not only what is new, but what part of rosacea that new option is actually designed to treat.

1. Emrosi — A Newer Oral Treatment for Inflammatory Rosacea

Emrosi is one of the newest oral prescription options for adults with inflammatory papules and pustules. It contains minocycline hydrochloride in a 40 mg extended-release capsule. The FDA approved it in November 2024, and its U.S. commercial launch began in 2025, so it remains a recent addition rather than a drug newly approved in 2026.

Two Phase 3 trials involving 653 adults with moderate-to-severe papulopustular rosacea compared Emrosi with placebo and doxycycline 40 mg. Emrosi produced greater reductions in inflammatory lesions and higher investigator-rated treatment success than both comparators after 16 weeks. The Phase 3 results support it as a newer option for inflammatory rosacea specifically. If persistent erythema, flushing, or visible vessels are the main problem, another treatment may still be needed.

2. Encapsulated Benzoyl Peroxide — A Newer Topical Option

Benzoyl peroxide is old. The newer part of Epsolay is the way it is delivered. Epsolay contains 5% benzoyl peroxide inside silica microcapsules that release the ingredient gradually. That matters because conventional benzoyl peroxide can be irritating, while rosacea-prone skin is often already sensitive.

The treatment is aimed at inflammatory lesions. In two Phase 3 trials involving 733 adults, 43.5% and 50.1% of people using encapsulated benzoyl peroxide were rated clear or almost clear after 12 weeks, compared with 16.1% and 25.9% using vehicle. The trials showed that the formulation can reduce rosacea bumps and pustules; they did not turn benzoyl peroxide into a treatment for every form of redness or flushing.

3. Newer Combination Treatments for Different Rosacea Symptoms

Another important change is that rosacea treatment increasingly accepts that one treatment may not need to do everything. Someone may have papules that respond to medication but still have persistent background redness. Another person may control inflammation but continue to see telangiectasia. In those situations, clinicians may combine or sequence treatments: topical or oral therapy for inflammatory lesions, a redness-targeting medication for persistent erythema, and laser or light treatment for visible vessels.

The National Rosacea Society now frames treatment around individual rosacea phenotypes rather than expecting one medication to control every feature. That is why “combination treatment” is part of the newer treatment landscape even though it is a strategy rather than a new drug.

4. Laser and IPL Treatments Are Becoming More Personalized

PDL, IPL, and vascular lasers are not new in 2026. The change is in how they are selected and used. Persistent erythema, scattered visible vessels, diffuse flushing, skin tone, vessel depth, and previous treatment response can all influence which device and settings make sense.

A person whose papules are already controlled but still has persistent redness may get more value from a vascular procedure than from adding another anti-inflammatory drug. Laser and light treatment can also be combined with medication when vascular and inflammatory features occur together. In other words, the progress here is better matching and combination, not a single new “2026 rosacea laser.”

5. PDE4 Inhibitors and New Anti-Inflammatory Treatments

PDE4 inhibitors are not routine rosacea treatment yet, but they represent a different way of targeting inflammation. PDE4 helps regulate inflammatory signaling inside cells, and PDE4-blocking drugs already have established uses in other inflammatory skin diseases. That success has led researchers to test whether the same pathway could help inflammatory rosacea.

Rosacea-specific PDE4 candidates have reached Phase 2 research, but that is still a long way from saying the class is ready for standard care. A drug can be approved for another skin disease and still remain investigational for rosacea. The 2026 rosacea pipeline still lists PDE4 inhibition as an active research direction rather than an established prescription option. Recent clinical-development reviews place it alongside other emerging mechanisms still being tested.

6. Biologics and Targeted Immune Therapies

Biologics raise an obvious question: could rosacea eventually be treated with the same kind of highly targeted immune therapy used in psoriasis? Researchers are exploring that possibility, but the evidence is still early.

Secukinumab, which targets IL-17A, has shown improvement in papule counts and overall severity in a small exploratory study of papulopustular rosacea. The study had no placebo group and only a small number of participants, so it is better interpreted as a signal that the pathway may be worth studying than as evidence that biologics are ready for routine rosacea treatment. In 2026, targeted immune therapy remains an investigational direction, not a standard next step after topical treatment fails.

7. Neurovascular Treatments for Flushing and Redness

Flushing is one reason rosacea research is moving beyond inflammation. Papules and pustules can often be treated with established anti-inflammatory therapies, but frequent flushing and persistent vascular redness can remain difficult for some patients. That has shifted attention toward the signals exchanged between sensory nerves and facial blood vessels.

PACAP and CGRP are two neuropeptides being studied in this area. In one controlled experiment, PACAP38 increased facial blood flow, flushing, and edema in people with erythematotelangiectatic rosacea, showing that changing one nerve-derived signal can directly change vascular symptoms. That study was mechanistic rather than a treatment trial.

CGRP inhibition has moved a little closer to treatment research. In a small open-label study, the CGRP-receptor antibody erenumab was associated with fewer days of flushing and erythema over 12 weeks. The study had no randomized comparison group, so it does not establish CGRP blockade as a standard rosacea treatment. It does show why neurovascular signaling is now being treated as a real therapeutic target rather than just part of the disease mechanism.

8. Nervous-System and Stress Support as a Complementary Approach

Stress management belongs to trigger control, not to treatment of the rosacea lesions themselves. Emotional stress is a commonly reported flare trigger, so reducing stress may be useful for someone whose flushing or symptoms repeatedly worsen during high-pressure periods. It will not remove persistent erythema, telangiectasia, or inflammatory lesions that remain when stress is low.

That layer of management can include breathing, mindfulness, regular activity, adequate sleep, therapy when anxiety is persistent, or another repeatable relaxation routine. Some people may also use ZenoWell Luna Plus as an optional ear-based taVNS wellness tool for relaxation. The reason to include any of these approaches is the same: stress has already been identified as a personal trigger. If symptoms continue just as often during calm periods, the priority shifts back toward other triggers and skin-directed treatment.

New Rosacea Treatments at a Glance

FAQ

What Is the Newest Treatment for Rosacea in 2026?

Emrosi is one of the newest major U.S. prescription additions. It was FDA-approved in November 2024 and commercially launched in 2025, and it is indicated for inflammatory papules and pustules in adults.

Is There a New Cure for Rosacea?

No. Current and emerging treatments control specific features of rosacea rather than cure the condition. The newer treatment landscape is mainly about expanding the ways clinicians can target inflammatory lesions, persistent redness, visible vessels, and difficult flushing.

What Is the Newest Treatment for Rosacea Redness?

There is no single newest option for every type of redness. Persistent erythema may be treated with redness-targeting medication or vascular procedures, visible vessels may respond to laser or IPL, and inflammatory redness improves when papules and pustules are controlled. Neurovascular treatments for difficult flushing remain investigational.

Are There New Laser Treatments for Rosacea?

PDL, IPL, and vascular lasers are established rather than new 2026 technologies. The main progress is more individualized device selection, treatment parameters, and combination with medical therapy.

Can Stress Make Rosacea Worse?

Yes. Emotional stress can trigger or worsen rosacea symptoms in some people, particularly flushing. Stress management helps with that trigger; it does not replace treatment of the underlying skin condition. Stress and rosacea flare-ups explains how to tell whether stress is actually part of your own flare pattern.